Malt welcome

Welcome to Ulf's freelance profile!

Malt gives you access to the best freelancers for your projects. Contact Ulf to discuss your project or search for other freelancer profiles on Malt.

Ulf Ericsson

Strategic Marketing in Life Science
  • Suggested rate
    €1,000 / day
  • Experience15+ years
  • Response rate100%
  • Response time1 hour
The project will begin once you accept Ulf's quote.
Location and workplace preferences
Location
Malmo, Sweden
Can work onsite in your office in
  • and around Malmo (up to 50km)
Verifications

Freelancer code of conduct signed

Read the Malt code of conduct
Verified email
Languages
Categories
Share this profile
These freelancer profiles also match your search criteria
Agatha FrydrychAF

Agatha Frydrych

Backend Java Software Engineer

Baptiste DuhenBD

Baptiste Duhen

Fullstack developer

Amed HamouAH

Amed Hamou

Senior Lead Developer

Audrey ChampionAC

Audrey Champion

Web developer

Skill set (14)
Ulf in a few words
I have extensive experience from leading Life Science Marketing and Business Development positions in the pharmaceutical drug product and medical device space. My experience stretches throughout the whole value chain from early development, new product planning, pre-launch and launch to life cycle management.

Team player motivated by the collaboration and dynamics in a strong team and network. My key drive is to see possibilities and by that creating a contagious positive attitude. Clear focus on meeting targets. As a person I am thorough in my analysis, curious and capable of quickly understanding complex context and issues on both “helicopter” and “granular” level. Professionalism is a key word to me, expressed by delivering high quality based on a clear purpose and goal.
Experience
  • Nanologica AB
    Senior Director Marketing and Business Development
    PHARMACEUTICALS INDUSTRY
    August 2021 - December 2023 (2 years and 5 months)
    Stockholm, Sweden
    Led Business Development, New Product Planning and Commercialization of a novel drug delivery technology platform with focus on applications in Biologics and Rare Diseases. Member of the corporate management team.

    Developed and implemented a new focused strategy with a new direction for the business area focusing on where the technology has its highest potential, balancing unmet needs, business opportunity and risks. To deliver on the strategy most effectively I have developed a road map clearly describing the way forward to clinic. I have also developed multiple brand strategies (including TPP, positioning, value proposition, business case etc.) for potential opportunities to assess product potentials and make priorities.
  • AstraZeneca
    Global Senior Director, Biopharmaceutical Business Unit
    PHARMACEUTICALS INDUSTRY
    April 2017 - July 2021 (4 years and 4 months)
    Gothenburg, Sweden
    Led the Global Device strategy for AstraZeneca’s inhaled portfolio, as well as the commercial part in the development of future inhalation devices, formulations, and platforms. Developed a Digital Health launch strategy and defined business models as well as developed a ROI model to assess suitable markets and business models for Digital Health launch.

    Appointed to lead several Workstreams in the Global Therapeutic Area and Disease Strategy.

    As member of the Core Global Project Team for Established Brands and Nebulisation I was engaged as subject matter expert with regards to the established brands portfolio. Commercial lead in all Business Development evaluations in the inhalation space. Member of the Global Sustainability team, deeply involved in all matters regarding the environmental aspects of AstraZeneca’s inhaled drug products cross the respiratory portfolio.
  • AstraZeneca
    Global Director, Global Product and Portfolio Strategy
    PHARMACEUTICALS INDUSTRY
    August 2014 - March 2017 (2 years and 8 months)
    Gothenburg, Sweden
    Global lead for a portfolio of six brands, worth $1.5bn annual sales combined. The biggest brand, Pulmicort®, grew under my leadership from flat $850mn to $1.2bn with double digit growth in three years by developing and implementing a new business model for Nebulised treatment. Led a cross-functional Global Project Team for the portfolio and member of the Core Global Project Team. Commercial lead in all Business Development evaluations and New Product Planning in the TA.

    Led the Global Device strategy for AstraZeneca’s inhaled portfolio. Commercial lead for all inhaler devices and formulations cross AZ commercialized portfolio as well as leading the commercial part for development of future inhalation devices, formulations, and platforms.
Recommendations
Education
  • Master of Science in Business Administration
    University of Lund
    1996